Edition:
India

Novartis AG (NOVN.S)

NOVN.S on Virt-X Level 1

83.30CHF
9:06pm IST
Change (% chg)

CHF-0.08 (-0.10%)
Prev Close
CHF83.38
Open
CHF83.28
Day's High
CHF83.56
Day's Low
CHF82.82
Volume
2,727,799
Avg. Vol
4,430,278
52-wk High
CHF85.40
52-wk Low
CHF69.50

Chart for

About

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines... (more)

Overall

Beta: 1.05
Market Cap(Mil.): CHF219,900.80
Shares Outstanding(Mil.): 2,616.84
Dividend: 2.75
Yield (%): 3.27

Financials

  Industry Sector
P/E (TTM): -- 31.10 16.58
EPS (TTM): -- -- --
ROI: -- 14.84 10.60
ROE: -- 16.32 14.19

BRIEF-Genmab Gets USD 50 Mln From Novartis For Lost Potential Milestones And Royalties​

* ANNOUNCES NOVARTIS’ INTENTION TO TRANSITION ARZERRA® (OFATUMUMAB) FROM COMMERCIAL AVAILABILITY TO LIMITED AVAILABILITY VIA COMPASSIONATE USE PROGRAMS FOR THE TREATMENT OF CLL IN NON-US MARKETS

12:42pm IST

Novartis's Kymriah wins speedy reviews in U.S., Europe

ZURICH Novartis has been granted fast-track reviews of its cell therapy Kymriah for blood cancers in the United States and Europe, the Swiss drugmaker said on Wednesday, as it seeks to expand the pool of patients eligible for the costly treatment.

17 Jan 2018

UPDATE 1-Novartis's Kymriah wins speedy reviews in U.S., Europe

ZURICH, Jan 17 Novartis has been granted fast-track reviews of its cell therapy Kymriah for blood cancers in the United States and Europe, the Swiss drugmaker said on Wednesday, as it seeks to expand the pool of patients eligible for the costly treatment.

17 Jan 2018

Novartis gets U.S. priority review for Kymriah for adults with lymphoma

ZURICH, Jan 17 Novartis has been ‍granted priority review for its cell therapy Kymriah for adults with a form of lymphoma by the U.S. Food and Drug Administration, the Swiss drugmaker said on Wednesday, as it seeks to expand use of the treatment in multiple blood cancers.

17 Jan 2018

BRIEF-FDA accepts Novartis submission of biosimilar version of Humira

* SANDOZ REGULATORY SUBMISSION FOR PROPOSED BIOSIMILAR ADALIMUMAB ACCEPTED BY FDA

16 Jan 2018

Novartis' Promacta receives FDA breakthrough designation for new indication

ZURICH Novartis drug Promacta has received breakthrough therapy designation from the U.S. Food and Drug Administration for first-line treatment of severe aplastic anemia (SAA).

04 Jan 2018

Novartis' Promacta receives FDA breakthrough designation for new indication

ZURICH, Jan 4 Novartis drug Promacta has received breakthrough therapy designation from the U.S. Food and Drug Administration for first-line treatment of severe aplastic anemia (SAA).

04 Jan 2018

MEDIA-Novartis's diclofinac injection flagged by India health ministry panel - Mint

- Note: Reuters has not verified this story and does not vouch for its accuracy

04 Jan 2018

Novartis breast cancer therapy gets FDA breakthrough designation

ZURICH Novartis's Kisqali (ribociclib) has won U.S. Food and Drug Administration breakthrough therapy designation for treating some breast cancer patients, the Swiss drugmaker said on Wednesday.

03 Jan 2018

Novartis breast cancer therapy gets FDA breakthrough designation

ZURICH, Jan 3 Novartis's Kisqali (ribociclib) has won U.S. Food and Drug Administration breakthrough therapy designation for treating some breast cancer patients, the Swiss drugmaker said on Wednesday.

03 Jan 2018

Earnings vs. Estimates